Loading song details...
ASH 2024 Dr Onyee Chan On Phase 1 Study Of CPX 351 Gilteritinib In FLT3 Mutated AML
No description available.
MP3 Download
Video Download
Related Songs
22:19
Multiple Myeloma ASH 2024 Highlights With Dr Robert Orlowski
2:16
ASH 2024 Dr Fnu Amisha Discusses Predictive Markers After BCMA CAR T Therapy In RRMM Patients
1:30:57
IMWG Conference Series Making Sense Of Treatment ASH 2024
4:21
What S New In CLL Therapies At ASH 2024 Dr Nicole Lamanna
1:47
ASH 2024 Dr Rachid Baz Discusses A Personalized Daratumumab Based Response Adapted Therapy
7:18
Dr Bose Shares Key MPN Highlights From ASH 2024
1:47
Dr Beth Faiman Shares ASH 2024 Highlights
13:33
Dr Banerjee Describes Practice Changing MM Data Presented At ASH 2024
6:18:15
Yale S Post ASH Review Highlights From The 2024 American Society Of Hematology Annual Meeting
2:47
ASH 2024 Dr Sameh Gaballa MD On High Response Rates With AZD0486 In Relapsed Refractory DLBCL
1:36:31
Latest Myeloma Updates From ASH 2024 Easy To Understand Insights For Patients And Care Partners
9:45
Dr Burke Pinpoints Top Trends From ASH 2024
1:22
ASH News TV 2024 A Palooza And Trainee Council
4:59
ASH News TV 2024 Welcome To Annual Meeting
9:47
New Frontiers In Myelofibrosis Care Presented At ASH 2024
3:02
ASH News TV 2024 Blood Launches New Journals
1:04
Dr Damian Green ASH 2024
7:36
Highlights In Myelofibrosis Research At ASH 2024 Experts Selections
12:26
ASH 2024 Dr Porcu Discusses Patient Reported Outcomes With Lacutamab In Cutaneous T Cell Lymphoma
3:58